8-K: BioLife Solutions Reports Strong 2025 Growth, Positive 2026 Outlook

BioLife Solutions announced robust fourth quarter and full year 2025 financial results, driven by its focused cell processing strategy, and provided optimistic 2026 guidance.

Summary

• Fourth quarter 2025 revenue from continuing operations was $24.8 million, an increase of 20% year-over-year.
• Full year 2025 revenue from continuing operations reached $96.2 million, up 29% year-over-year.
• GAAP gross margin for Q4 2025 was 63%, with non-GAAP adjusted gross margin at 64%.
• GAAP net income for Q4 2025 was $2.1 million, or $0.04 per share, compared to a net loss of $1.2 million in Q4 2024.
• Adjusted EBITDA for Q4 2025 was $6.9 million, representing 28% of total revenue, up from $3.7 million (18% of revenue) in Q4 2024.
• Full year 2025 GAAP net loss was $12.1 million, or $0.25 per share, compared to $8.8 million in 2024.
• Full year 2025 adjusted EBITDA was $25.0 million, or 26% of revenue, compared to $13.3 million (18% of revenue) in 2024.
• The company completed the sale of its evo subsidiary on October 6, 2025, for $25.5 million in cash, streamlining its focus to cell processing.
• BioLife's biopreservation media is utilized in approximately 250 ongoing commercially sponsored CGT clinical trials in the U.S., holding over 70% market share, including nearly 80% of late-stage (Phase III) trials.
• Biopreservation media is embedded in 16 unique commercial CGT products as of December 31, 2025, with expectations for 7 additional product approvals (including 5 unique therapies) over the next 12 months.
• Cash, cash equivalents, and marketable securities stood at $120.2 million as of December 31, 2025.
• For 2026, the company expects revenue between $112.5 million and $115.0 million, representing 17%-20% growth over 2025, and anticipates full year GAAP profitability.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, highlighting strong revenue growth, significant adjusted EBITDA expansion, a return to quarterly GAAP profitability, and a clear strategic focus following divestitures, all supported by optimistic 2026 guidance.

Positives

• Achieved strong revenue growth of 20% in Q4 2025 and 29% for the full year 2025 from continuing operations.
• Demonstrated significant adjusted EBITDA expansion, reaching $6.9 million (28% of revenue) in Q4 2025 and $25.0 million (26% of revenue) for the full year 2025.
• Returned to GAAP net income of $2.1 million in Q4 2025, a positive shift from a net loss in the prior year quarter.
• Successfully completed a strategic divestiture of the evo subsidiary for $25.5 million, establishing BioLife as a focused, pure-play cell processing company.
• Maintains a dominant market share (over 70%) in biopreservation media for U.S. commercially sponsored CGT clinical trials, including nearly 80% of late-stage trials.
• Products are increasingly embedded in commercial CGT therapies, with 16 unique products as of year-end 2025 and 7 additional approvals expected in the next 12 months.
• Provided optimistic 2026 financial guidance, projecting 17%-20% revenue growth and a return to full year GAAP profitability.

Negatives

• GAAP gross margin slightly decreased to 63% in Q4 2025 from 66% in Q4 2024, and to 65% for full year 2025 from 67% in 2024.
• Full year 2025 GAAP net loss increased to $12.1 million from $8.8 million in 2024.
• Full year 2025 GAAP operating loss increased to $16.6 million from $4.5 million in 2024.

Risks

• Forward-looking statements involve risks and uncertainties that are difficult to predict and could cause actual results to differ materially from expectations.

Future Outlook

BioLife Solutions expects 2026 revenue to be between $112.5 million and $115.0 million, representing 17%-20% growth over 2025. The company anticipates GAAP gross margins in the mid-60% range, achieving full year GAAP profitability, and continued expansion of adjusted EBITDA margin. Management projects sustained growth in the cell and gene therapy market, driven by new therapy approvals, geographic expansions, and an improving biotech funding environment.

Management Comments

• "2025 was a transformative year for BioLife. We delivered 29% revenue growth, led by sustained strength in our biopreservation media franchise and completed a strategic divestiture that firmly established BioLife as a focused, pure-play cell processing company centered on high-value, recurring revenue. With a streamlined cost structure and a scaled core business, we are now realizing the operating leverage inherent in our model." Roderick de Greef, Chairman and CEO.
• "Looking to 2026, we expect growth across our portfolio, operating margin expansion, continued improvement in adjusted EBITDA, and full year GAAP profitability." Roderick de Greef, Chairman and CEO.
• "Continued growth of the CGT end market – including new, unique therapy approvals, geographic expansions, a shift to earlier lines of treatment and additional indications for approved therapies – will further embed our gold-standard tools into more commercial therapies that drive demand. An improving biotech funding environment, strategic investment by large pharma, and ongoing clinical progress underscore this markets long-term attractiveness and provides a meaningful opportunity ahead for BioLife." Roderick de Greef, Chairman and CEO.

Industry Context

StockSavvy.ai notes that BioLife Solutions' strong performance and optimistic outlook align with the broader growth trajectory of the cell and gene therapy (CGT) market. The company's high market share in biopreservation media for clinical trials and increasing embedment in commercial therapies position it well to capitalize on the expanding demand driven by new therapy approvals and increased biotech funding, a trend observed across the specialized life sciences tools sector.

Stakeholder Impact

• Shareholders: Potential for increased share value due to strong financial performance, strategic clarity, and positive future guidance.
• Customers (CGT developers): Continued access to 'gold-standard tools' and services, supporting their ongoing clinical trials and commercial therapy development.
• Employees: Enhanced job stability and potential for growth within a focused and expanding company.

Next Steps

• Management will host a conference call and live webcast on February 26, 2026, at 4:30 p.m. ET to discuss results and provide a business update.
• Expectation for 7 additional product approvals (including 5 unique therapies, geographic expansions, earlier lines of treatment, or new indications) for biopreservation media over the next 12 months.

Key Dates

Recommendation

The company demonstrated robust financial performance in 2025, marked by significant revenue growth and substantial adjusted EBITDA expansion, indicating strong operational leverage post-divestiture. The return to GAAP net income in Q4 2025 and the optimistic 2026 guidance, including projected full-year GAAP profitability, suggest a positive inflection point. BioLife Solutions maintains a dominant market position in a high-growth industry (CGT), with its products embedded in numerous clinical trials and commercial therapies. This strong market position, combined with a clear strategic focus and healthy cash reserves, makes it an attractive investment.

Keywords

BioLife Solutions, BLFS, Cell and Gene Therapy, CGT, Biopreservation Media, CellSeal, Human Platelet Lysate, hPL, Financial Results, Earnings, Q4 2025, Full Year 2025, 2026 Guidance, Biotech, Life Sciences